Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacherstr. 6, Würzburg, 97080, Germany.
Nuclear Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany.
Mol Imaging Biol. 2022 Aug;24(4):659-665. doi: 10.1007/s11307-022-01717-1. Epub 2022 Mar 21.
CXCR4-directed positron emission tomography/computed tomography (PET/CT) has been used as a diagnostic tool in patients with solid tumors. We aimed to determine a potential correlation between tumor burden and radiotracer accumulation in normal organs.
Ninety patients with histologically proven solid cancers underwent CXCR4-targeted [Ga]Ga-PentixaFor PET/CT. Volumes of interest (VOIs) were placed in normal organs (heart, liver, spleen, bone marrow, and kidneys) and tumor lesions. Mean standardized uptake values (SUV) for normal organs were determined. For CXCR4-positive tumor burden, maximum SUV (SUV), tumor volume (TV), and fractional tumor activity (FTA, defined as SUV x TV), were calculated. We used a Spearman's rank correlation coefficient (ρ) to derive correlative indices between normal organ uptake and tumor burden.
Median SUV in unaffected organs was 5.2 for the spleen (range, 2.44 - 10.55), 3.27 for the kidneys (range, 1.52 - 17.4), followed by bone marrow (1.76, range, 0.84 - 3.98), heart (1.66, range, 0.88 - 2.89), and liver (1.28, range, 0.73 - 2.45). No significant correlation between SUV in tumor lesions (ρ ≤ 0.189, P ≥ 0.07), TV (ρ ≥ -0.204, P ≥ 0.06) or FTA (ρ ≥ -0.142, P ≥ 0.18) with the investigated organs was found.
In patients with solid tumors imaged with [Ga]Ga-PentixaFor PET/CT, no relevant tumor sink effect was noted. This observation may be of relevance for therapies with radioactive and non-radioactive CXCR4-directed drugs, as with increasing tumor burden, the dose to normal organs may remain unchanged.
CXCR4 导向的正电子发射断层扫描/计算机断层扫描（PET/CT）已被用作实体瘤患者的诊断工具。我们旨在确定肿瘤负荷与正常器官放射性示踪剂积聚之间的潜在相关性。
90 名经组织学证实的实体癌患者接受了 CXCR4 靶向[Ga]Ga-PentixaFor PET/CT 检查。在正常器官（心脏、肝脏、脾脏、骨髓和肾脏）和肿瘤病变中放置了感兴趣的体积（VOI）。确定正常器官的平均标准化摄取值（SUV）。对于 CXCR4 阳性肿瘤负荷，计算最大 SUV（SUV）、肿瘤体积（TV）和肿瘤活性分数（FTA，定义为 SUV x TV）。我们使用 Spearman 秩相关系数（ρ）来推导正常器官摄取与肿瘤负荷之间的相关指数。
未受影响器官的 SUV 中位数为脾脏 5.2（范围 2.44-10.55），肾脏 3.27（范围 1.52-17.4），其次是骨髓 1.76（范围 0.84-3.98）、心脏 1.66（范围 0.88-2.89）和肝脏 1.28（范围 0.73-2.45）。肿瘤病变的 SUV（ρ≤0.189，P≥0.07）、TV（ρ≥-0.204，P≥0.06）或 FTA（ρ≥-0.142，P≥0.18）之间无显著相关性。
在接受[Ga]Ga-PentixaFor PET/CT 成像的实体瘤患者中，未观察到相关的肿瘤清除效应。这一观察结果可能与放射性和非放射性 CXCR4 导向药物的治疗有关，因为随着肿瘤负荷的增加，正常器官的剂量可能保持不变。
